Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) EPS (Weighted Average and Diluted) (2022 - 2025)

PAVmed has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$5.52 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 139.12% year-over-year to -$5.52; the TTM value through Dec 2025 reached -$6.21, down 174.19%, while the annual FY2025 figure was -$5.63, 137.79% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$5.52 at PAVmed, down from -$0.29 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $14.11 in Q4 2024 and troughed at -$14.25 in Q4 2022.
  • A 4-year average of -$1.42 and a median of -$1.56 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 720.69% in 2023 and later surged 831.09% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$14.25 in 2022, then skyrocketed by 86.46% to -$1.93 in 2023, then surged by 831.09% to $14.11 in 2024, then tumbled by 139.12% to -$5.52 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for PAVM at -$5.52 in Q4 2025, -$0.29 in Q3 2025, and -$0.74 in Q2 2025.